Why the study?
Does moxifloxacin 400 mg increase the QTc interval in healthy subjects compared to placebo?
Does moxifloxacin 400 mg increase the QTc interval in healthy subjects compared to placebo?
Moxifloxacin 400 mg reliably increases the QTc interval, supporting its use as a positive control in thorough QT studies and demonstrating that predose baselines are sufficient compared to time-matched baselines.
Answers are grounded in this paper and cite their sources.
Confirms moxifloxacin 400 mg as reliable positive control for TQT studies; supports predose baselines as sufficient versus time-matched.
A number of issues have remained unanswered in the design of "thorough QT"(TQT) studies. In this randomized, placebo-controlled, two-period crossover study in 20 healthy subjects, replicate electrocardiograms (ECGs) were recorded on a digital 12-lead Holter recorder, extracted in a core ECG laboratory, and interpreted manually by a cardiologist. The observed within-subject variability was slightly greater when time-matched baselines were employed than when predose baselines were employed, whereas the magnitude of the increase in QTc was similar for both. Moxifloxacin 400 mg was associated with an observed 7.5-12.5 ms increase in the mean placebo- and baseline-corrected QTc interval. A PK-QTc model estimated a 3.9 ms increase in the QTc interval for every 1,000 ng/ml increase in moxifloxacin concentration. The QTc increases associated with moxifloxacin support the appropriateness of its use as a positive control in TQT studies. This crossover study failed to justify the use of time-matched baselines rather than the less resource-intensive predose definition of baseline.
No takes yet. Share an insight, caveat, or question.
Bloomfield et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: